Femåriga erbjudanden för leverans av peptider: Lektioner från Amylyx och Bachem

Pillar 1: Kvantifiera din efterfrågeosäkerhet innan du åtar dig

Det vanligaste felet i långsiktiga peptidleveransavtal är bindande volymåtaganden till en efterfrågeprognos som inte har stresstestats mot programmets faktiska kliniska och regulatoriska osäkerhet.

Amylyx-Bachem-avtalet skjuter upp minimiköpsåtaganden till 2028 — minst två år efter undertecknandet. Det gapet är inte generositet; det är ett erkännande att avexitides kommersiella volymer beror på tidpunkten för FDA-godkännande, etikettens omfattning, och beslut om åtkomst till betalare som förblir olösta vid kontraktets genomförande. Strukturen separerar kapacitetsreservation (vilket kan göras tidigt) från volymengagemang (som börjar först när efterfrågekuvertet blir mer lätthanterligt).

Innan du accepterar en minsta årlig kvantitet (MAG) klausul, kör tre scenarier över din prognosmodell:

• Basfodral: godkännande i förväntat fönster, etiketten matchar målindikationen

• Fördröjningsfall: tolv till arton månaders godkännandefördröjning, ingen inverkan på indikationens omfattning

• Nackdelen fall: smalt etikettgodkännande, begränsat marknadstillträde, eller nedprioritering av pipeline

Om MAQ överstiger volymen för nedsidan med mer än 20–25 %, du köper i praktiken en försäkring för en kapacitetsnivå som du kanske aldrig kommer att behöva – och betalar take-or-pay-straff när du misslyckas med att absorbera den. Förhandla om avvecklingsbestämmelser som tillåter volymminskningar som svar på dokumenterade regulatoriska eller kommersiella triggers. Standardspråket från SEC-arkiverade API-leveransavtal tillåter sponsorer att åberopa force majeure eller väsentliga negativa förändringsklausuler, men dessa rättsmedel är svåra att åberopa och alltid ifrågasatta; en förförhandlad nedtrappningsmekanism är mycket mer operativt användbar.

⚠️ Felläge: Undertecknande av en platt MAQ kopplad till grundläggande lanseringsantaganden, sedan absorbera take-or-pay-avgifter på 20–40 % av den obeställda volymen när ett försenat godkännande eller begränsad etikett komprimerar det kommersiella upptaget under prognosen.

Pillar 2: Förstå vad du faktiskt betalar för i reservationsekonomi

Polypeptidgruppens termblad inkluderade en $30 miljoner förskottsavgift för kapacitetsreservation – ett antal som är tillräckligt stort i absoluta tal för att kunna granskas avsevärt på styrelsenivå, men som återspeglar en allt mer normal kostnadsstruktur för GMP-peptidtillverkningskapacitet i stor skala.

Reservationsekonomi i peptid CDMO-avtal inkluderar nu vanligtvis två distinkta finansiella instrument som ofta blandas ihop:

1. Reservationsavgift för kapacitet (CRF): en fast betalning, ofta ej återbetalningsbar eller endast delvis krediterbar mot framtida inköpsfakturor, som säkrar namngivna tillverkningsluckor för en definierad peptid, renhetsspecifikation, batchstorlek, och släppstandard. Avgiften kompenserar CDMO för att ha kapacitet mot ett fast åtagande snarare än att fylla den opportunistiskt med andra kunders kampanjer.

2. Underhållsavgifter: återkommande betalningar som täcker kvalitetskontroll, underhåll av regulatoriska filer, metodretention, och periodiska kampanjförberedande aktiviteter under perioder med låg eller ingen aktiv tillverkning - vad Amylyx-Bachem-avslöjandet refererar till som "underhållsavgifter och -kostnader."

Distinktionen har betydelse för finansiell modellering. En CRF är en sänkt kapitalkostnad kopplad till optionsvärdet; underhållsavgifter är återkommande driftskostnader som fortsätter även under år då inga tillverkningskörningar inträffar. Båda ska ingå i nettonuvarande kostnadskalkylen över avtalsperioden.

Innan du skriver under, hämta svar på fyra frågor från utkastet till avtal:

1. Är CRF fullt kreditvärdig, delvis kreditvärdig, eller förverkas vid avbokning?

2. Under vilka villkor omvandlas CRF till en verkställbar skyldighet (dvs., when does the option become a liability)?

3. What triggers a maintenance fee invoice, and what is the audit right attached to it?

4. If the primary site cannot fulfill a reserved slot, does the CDMO have an obligation to provide an equivalent slot at an alternate qualified facility — and within what timeline?

The third question is frequently underdefined in first-draft agreements. Tier-1 CDMOs operating at scale commonly include language allowing unilateral rescheduling of reserved slots within a defined window, sometimes as short as thirty days, with no monetary remedy to the sponsor. Negotiate explicit remedies — accelerated delivery rights, priority rebooking within a defined period, or fee credits — before the agreement is executed.

Peptidsyntes Per current CDMO pricing analysis, Tier-1 CDMOs now routinely require 10–20% advance reservation deposits for research-scale agreements and 40–50% upfront non-refundable commitments for commercial-scale capacity. Understanding where your deal sits in that range — and why — is a foundational negotiation input.

Pillar 3: Karta teknisk-överföringsberedskap innan du låser in en partner

A supply agreement binds you commercially to a specific CDMO partner. Technical transfer complexity determines how easily you can exit that binding if circumstances change — and how much switching costs will constrain your negotiating leverage on renewals.

Peptide Contract Manufacturing Pricing Trends Q2 2026 places technology transfer costs for complex peptide APIs at $300,000–$800,000 or more, depending on process complexity, analytical method portfolio size, and GMP documentation burden. That range creates significant lock-in for programs with difficult sequences, multi-step modifications, or extensive stability-indicating method sets. The higher your transfer cost, the more leverage your CDMO has at renewal — and the more important it is to build transfer readiness into the original agreement.

Technical transfer readiness is best evaluated across four dimensions before signing:

An agreement that does not address method transfer protocol ownership, DMF filing rights, or post-agreement analytical record retention is one that hands the CDMO de facto veto power over any future transition. Negotiate:

• Sponsor access to batch records and analytical data within a defined period of request

• A right to conduct technical transfer to a qualified secondary or Syntetiska peptider tertiary site during the agreement term (not only at termination)

• Specific timelines and cost-sharing provisions for any required re-validation at a new site

De EMA Guideline on the Development and Manufacture of Synthetic Peptides provides the regulatory baseline for what analytical controls must be in place for GMP-grade synthetic peptide APIs. Your transfer readiness assessment should verify that the CDMO’s current control strategy satisfies this standard — not merely that they assert it does.

För tips: Request a “transfer readiness simulation” as part of final due diligence: ask the CDMO to provide the batch record index, method list, and DMF chapter inventory they would need to transfer to demonstrate readiness. Gaps in that inventory are negotiation leverage before signing — they become contractual disputes after.

Pillar 4: Bygg in beredskapsförsörjning i avtalsarkitekturen, Inte som en eftertanke

The Amylyx-Bachem agreement is explicitly non-exclusive: Bachem is one of two simultaneously engaged CDMOs, with Polypeptide Group holding a parallel supply commitment. This structural choice reflects a clear risk management posture — single-source dependence for a commercial peptide API is no longer considered acceptable practice by biopharma legal and supply chain teams who have experienced the post-2020 supply disruption environment.

Dual-sourcing for peptide APIs is not simply about having a backup vendor on file. A backup vendor that has not completed analytical comparability, process qualification, or regulatory file alignment is operationally unavailable when you need it. The operational standard, validated by building a resilient peptide supply chain, is a staggered second-source protocol:

Fas 1 (Months 1–3): Desk audit and analytical method transfer to secondary vendor. CoA comparability study using split-lot samples. No active manufacturing commitment.

Fas 2 (Months 4–9): Pilot comparability batches at secondary site. Analytical equivalence assessment for identity (ESI-MS eller MALDI-TOF), renhet (RP-HPLC), and impurity profiles. Regulatory file alignment.

Fas 3 (Pågående): Standing bridge allocation of 10–20% of routine purchase volume to secondary vendor. This maintains the secondary site’s production continuity and team familiarity with the process without incurring full commercial duplication costs.

The contingency sourcing provision in the primary supply agreement should explicitly address:

• The sponsor’s right to qualify and activate a secondary source during the agreement term, without triggering a breach-of-exclusivity claim (particularly if the primary agreement contains any preferred-supplier language)

• Defined escalation triggers that convert the secondary vendor from standby to primary allocation — delivery SLA failures, batch release failures above a defined frequency threshold, regulatory action, or material financial distress

• Supplier switching timeline commitments: what is the maximum number of days from trigger activation to first commercial batch delivery from the secondary source?

Per the dual-sourcing strategy guidance for biopharma, a 70/30 eller 60/40 commercial split across primary and secondary CDMOs is an operational benchmark that maintains secondary-source readiness without imposing equivalent cost to full parallel manufacturing.

⚠️ Felläge: Qualifying a secondary CDMO on paper but not in practice — no pilot batches completed, no analytical comparability data on file, no regulatory filing amendments to add the alternate site. When the primary site has a capacity shortfall or quality excursion, the backup cannot legally supply commercial-grade material.

Pillar 5: Definiera ansvarsområden för releasetestning med kontraktuell precision

Release testing responsibility is the most commonly under-specified element in peptide API supply agreements, and the most consequential when a batch fails or a specification dispute arises.

The Amylyx-Bachem agreement allocates testing and supply responsibilities to Bachem as the manufacturer, with Amylyx retaining product specification authority and final lot disposition rights as the sponsor/applicant. This is the standard architecture under ICH Q7 and standard industry quality agreements — but the details within that architecture matter enormously.

For a GMP synthetic peptide API, minimum release specifications require orthogonal analytical coverage per regulatory guidance. Enligt PolypPeptide’s CMC quality control white paper, lot release specifications must be sufficient to establish identity, renhet, styrka, and where applicable, säkerhet (endotoxin, sterilitet) of the peptide API. A practical minimum release panel includes:

Beyond the panel itself, the quality agreement attached to the supply agreement must clearly assign responsibility for:

• Testing authority: who performs each test, and at which site (CDMO QC, sponsor QC, or independent third-party laboratory)?

• OOS investigation ownership: when a result falls outside specification, who initiates the investigation, what is the timeline, and what authority does the CDMO have to release a lot pending investigation resolution?

• Lot disposition authority: the CDMO typically performs provisional internal QC disposition; the sponsor retains final release authority for GMP lots intended for clinical or commercial use

• CoA format and data retention: the CoA must include batch number, all test results with raw data references (kromatogram, spektra), analyst ID, och releasedatum. Data retention obligations and sponsor access rights should be defined contractually, not left to the CDMO’s internal SOPs

This distribution of testing and disposition authority is the contractual backbone of your lot-level risk management. When a batch fails, ambiguity about who owns the investigation or the release decision translates directly to timeline risk and regulatory exposure.

Tillämpa ramverket: En checklista för förhandssignatur

The five pillars above convert to a structured pre-signature review that can be completed across a standard legal and technical due diligence cycle. For each pillar, the minimum acceptance condition is:

Any cell left blank or answered with “to be defined” before signing is a gap that will need to be resolved — under worse conditions — after execution.

Arbeta med din CDMO-partner om avtalsvillkor

The framework above is an evaluation and negotiation tool, not a prescriptive contract template. Real supply agreement negotiations involve counterpart constraints, market capacity realities, and relationship context that generic checklists cannot capture. The most productive outcome of applying this framework is a structured conversation with your CDMO counterpart about which provisions are standard, which are negotiable, and which require creative structural solutions.

For biopharma development teams building peptide programs from the milligram-to-kilogram scale, having a CDMO partner with explicit expertise in technical transfer, analytical method development, and quality agreement architecture reduces the friction in each of these five areas. MOL Ändringar supports peptide synthesis programs across the full development continuum — from complex custom sequences requiring 300+ functional group modifications to GMP-compatible production in Class 100 cleanroom environments with full HPLC, MS, and endotoxin QC — and can provide a technical feasibility assessment to help teams understand their specific agreement risk profile before negotiations begin.

The Amylyx-Bachem agreement, read at the level of its contractual mechanics rather than its headline announcement, is a useful reference point. Every team entering a multi-year peptide supply commitment should be able to account for each of the five pillars described above — not because the deal terms are identical to Amylyx’s, but because the categories of risk are.

Reviewed by the MOL Changes Peptide Science Team. MOL Changes is a commercial-stage peptide synthesis and CDMO services provider; the framework in this article reflects industry-standard practice and publicly available regulatory guidance, not proprietary claims.